Definitive Healthcare reported a Q1 2026 revenue of $55.9 million, a 6% decline year-over-year, yet still at the high end of guidance. The company achieved an adjusted EBITDA of $15.3 million, reflecting a 27% margin, up 260 basis points year-over-year, driven by operational efficiencies. Notably, subscription revenue fell 7%, while professional services revenue surged 25%, indicating a shift in business dynamics. However, deferred revenue and remaining performance obligations (RPO) declined significantly, raising concerns about future revenue visibility.
The decline in the life sciences segment continues to weigh on overall performance, with management citing pressures from claims disruptions and a transition to single-year contracts. Despite these challenges, the company has seen improvements in customer metrics, including net dollar retention and the highest win-back count in three years, suggesting a positive trajectory in customer engagement.
Looking ahead, the company projects further revenue declines for Q2 but maintains confidence in adjusted EBITDA growth due to strategic investments in AI and operational improvements. This focus on margin optimization amidst declining top-line growth will be critical for investor sentiment moving forward.
Source: fool.com